Keywords: Galapagos, Abbott Labs, Rheumatoid arthritis, GLPG0778, Autoimmune diseases, Licensing accord

Galapagos leaps on $1.35 billion RA drug deal with Abbott Labs

Article | 01 March 2012

Print This

Belgian drug developer Galapagos (Euronext: GLPG) saw its shares rocket 27% to a record high 13.89 euros yesterday, after it revealed that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in